Analysis of acamprosate in beagle dog plasma by LC-MS-MS

Abstract

A rapid, sensitive, and specific analytical method was developed and validated to quantify acamprosate calcium in beagle dog plasma. The method employs a single plasma protein precipitation, and the analytes are separated by chromatography on an Acquity UPLC HSS T3 column and analyzed by mass spectrometry in the multiple reaction monitoring (MRM) mode. The method has a chromatographic run time of 1.25 min and a linear calibration curve over the range 200-10000 ng/mL (r(2)>0.9994). The intra-day and inter-day accuracy and precision were within 10.0% for the analyte. Acamprosate was stable during all sample storage, preparation, and analytical periods. This method was employed in a pharmacokinetic study of an acamprosate 333 mg enteric-coated tablet in 8 male beagle dogs that received single 666 mg doses (333 mg x 2 tablets). The proposed method enables identification and quantification in pharmacokinetic studies of acamprosate in beagle dog plasma.

Pharmacokinetics of Acamprosate Calcium in Healthy Chinese Subjects after Oral Administration of Three Dosage Levels

“…Wed eveloped and validated anLC-MS-MS method for determination of acamprosatecalciumi nh umanp lasma.The method isr apid,sensitiveand highlys elective withanLLOQ of 2.0ng/mLusing 150 l Lhumanp lasma.Itw asproved superiorin sensitivity,selectivity and speed of analysist othe previouslyr eported methods [4][5][6].…”

Determination of acamprosate in human plasma by UPLC–MS/MS: Application to therapeutic drug monitoring

“…Very few studies have been carried out to determine acamprosate in human plasma (Chabenat et al, 1987; Ghosh et al, 2011, 2012; Girault et al, 1990; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009). Liquid chromatography with fluorescence or electrochemical detection (Chabenat et al, 1987), gas chromatography–mass spectrometry (Girault et al, 1990) and liquid chromatography–tandem mass spectrometry (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009) methods were used in the studies.…”

“…Very few studies have been carried out to determine acamprosate in human plasma (Chabenat et al, 1987; Ghosh et al, 2011, 2012; Girault et al, 1990; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009). Liquid chromatography with fluorescence or electrochemical detection (Chabenat et al, 1987), gas chromatography–mass spectrometry (Girault et al, 1990) and liquid chromatography–tandem mass spectrometry (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009) methods were used in the studies. Some of these studies need complex sample preparation procedures such as derivatization, solid‐phase extraction and evaporation with a nitrogen stream (Chabenat et al, 1987; Girault et al, 1990; Kanala et al, 2013; Luo et al, 2015; Xu et al, 2009), while others use basic protein precipitation (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Rhee et al, 2008).…”

“…Liquid chromatography with fluorescence or electrochemical detection (Chabenat et al, 1987), gas chromatography–mass spectrometry (Girault et al, 1990) and liquid chromatography–tandem mass spectrometry (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009) methods were used in the studies. Some of these studies need complex sample preparation procedures such as derivatization, solid‐phase extraction and evaporation with a nitrogen stream (Chabenat et al, 1987; Girault et al, 1990; Kanala et al, 2013; Luo et al, 2015; Xu et al, 2009), while others use basic protein precipitation (Ghosh et al, 2011, 2012; Hammarberg et al, 2010; Rhee et al, 2008). Also, some of the studies presented in the literature include a calibration range suitable for therapeutic drug monitoring (Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009).…”

“…In the literature, there are very few analytical methods for the determination of acamprosate in human plasma (Chabenat, Ladure, Blanc‐Continsouza, Boismare, & Boucly, 1987; Ghosh, Jha, Shinde, & Chakraborty, 2011; Girault, Gobin, & Fourtillan, 1990; Hammarberg et al, 2010; Kanala et al, 2013; Luo et al, 2015; Rhee et al, 2008; Xu et al, 2009). All of these methods were developed for the pharmacokinetics studies.…”